Hey mate, the ' .... so no no dollars were mentioned so what ...', unfortunately I believe it matters a heck of a lot.
Of the webinar, (originally allowing for 1 and half hrs or so), in the twenty five minutes it went for .... future funding got maybe less than 2 minutes discussion!
Future funds to source the immunotherapies division is absolutely vital if it is to go ahead, not going to be good enough to be relying on projected future profits from the other divisions to cover this.
Am sure WP and team absolutely turning over every stone to remedy this, if he can he will be a 'rainmaker', if not am sure that nobody else could have done any better! I really believe that.
Just wish that this company had the clout that the giants, CSL, Merck etc, have.
This is why I am starting to get a feeling that Ahz could be a target of a opportunistic takeover, if all their science and immunotherapies IP is as good as the company and its shareholders believe.
Cheers.
- Forums
- ASX - By Stock
- AVR
- Ann: Admedus Releases Results of HSV-2 Phase IIa Study
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-270
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.30 |
Change
-0.380(2.42%) |
Mkt cap ! $323.4M |
Open | High | Low | Value | Volume |
$15.70 | $15.94 | $15.02 | $290.0K | 18.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 280 | $15.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.57 | 779 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 280 | 15.100 |
2 | 96 | 15.020 |
1 | 15 | 15.010 |
2 | 582 | 15.000 |
1 | 1000 | 14.850 |
Price($) | Vol. | No. |
---|---|---|
15.570 | 779 | 1 |
15.930 | 250 | 1 |
15.940 | 554 | 1 |
15.950 | 848 | 2 |
16.000 | 1250 | 2 |
Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |